-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 25, U.
On April 25, U.
In this clinical trial evaluating NKX101 in the treatment of relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), all subjects (21 patients) had experienced multiple prior treatments and Among the patients with multiple relapses and poor prognosis, 20 had been treated with the BCL-2-targeted drug Venetoclax, and 4 had been treated with allogeneic hematopoietic stem cell transplantation
Leukemia Stem Cells 8 8 8 8 8
From the published data, NKX101 treatment was well tolerated, and no CAR-T -like toxicities, such as cytokine release syndrome (CRS) and neurotoxicity, were observed at any dose; neither graft-versus-host was observed GvHD and NKG2D CAR-NK-related AEs; more serious adverse events were observed, including myelosuppression, infection , etc.
CAR -T infection8
The most intriguing clinical data is that high-dose ( 10x108 or 15x108 CAR-NK cells, 3 infusions) showed a good response in AML, with 3 CRs in 5 subjects, of which 2 had minimal MRD.
The most intriguing clinical data is that high-dose ( 10x108 or 15x108 CAR-NK cells, 3 infusions) showed a good response in AML, with 3 CRs in 5 subjects, of which 2 had minimal MRD.
In fact, as early as 2018, Celyad developed CYAD-01/02 (a CAR-T cell therapy targeting NKG2D ligands), and reported that some patients with r/r AML receiving NKG2D CAR-T therapy had obtained Complete relief
leave a message here
